CJC-1295 (WITH DAC)
CJC-1295 with DAC is a modified GHRH analog studied for extended receptor interaction and endocrine signaling pathway analysis [1,2].
This peptide is for research purposes only. Not for human consumption.
Description
DAC-Enhanced Stability
The Drug Affinity Complex (DAC) extends peptide persistence, allowing researchers to examine prolonged signaling effects [1].
Endocrine Signaling Research
Studies explore extended GHRH receptor activation and downstream endocrine pathway behavior [2].
Comparative Analog Analysis
CJC-1295 with DAC is often compared with non-DAC variants to evaluate signaling duration and pathway kinetics [1].
Key Specs
- Peptide class: GHRH analog (DAC-modified)
- Research context: endocrine signaling
- References: PubChem, PubMed [1,2]
Referenced Citations
- PubChem, CJC-1295: https://pubchem.ncbi.nlm.nih.gov/compound/CJC-1295
- PubMed, CJC-1295 and DAC modification: https://pubmed.ncbi.nlm.nih.gov/18981485/
DAC-Enhanced Stability
The Drug Affinity Complex (DAC) extends peptide persistence, allowing researchers to examine prolonged signaling effects [1].
Endocrine Signaling Research
Studies explore extended GHRH receptor activation and downstream endocrine pathway behavior [2].
Comparative Analog Analysis
CJC-1295 with DAC is often compared with non-DAC variants to evaluate signaling duration and pathway kinetics [1].
Key Specs
- Peptide class: GHRH analog (DAC-modified)
- Research context: endocrine signaling
- References: PubChem, PubMed [1,2]
Referenced Citations
- PubChem, CJC-1295: https://pubchem.ncbi.nlm.nih.gov/compound/CJC-1295
- PubMed, CJC-1295 and DAC modification: https://pubmed.ncbi.nlm.nih.gov/18981485/
Reviews
There are no reviews yet.